13.12
+4.96%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neuropace
From its filings with the US Securities and Exchange Commission
Neuropace is based in Mountain View, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker NPCE. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $100.0m and a net loss of $21.5m. At that date it held total assets of $105.6m and shareholders' equity of $19.0m.
We are a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring and analyzing the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with imperceptible electrical pulses to prevent seizures, our RNS System is programmed by clinicians to deliver the precise amount of therapy when and where it is needed and provides exceptional clinical outcomes with approximately three minutes of stimulation on average per day. Our RNS System is also the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care. We believe the therapeutic advantages of our RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment. As of December 31, 2025, over 8,000 patients have received our RNS System.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 22 Apr 2021
- Employees
- 209
- Website
- neuropace.com ↗
- Head office
- 455 N. BERNARDO AVENUE, MOUNTAIN VIEW, CA, 94043
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Mr. Frank FischerIndependent Chairman of the Board, since 1997$172,159
- Mr. Joel BeckerPresident, Chief Executive Officer, Director, since 2023$3.0m
- Mr. Patrick WilliamsChief Financial Officer
- Dr. Martha MorrellChief Medical Officer$1.2m
- Ms. Lisa AndradeIndependent Director$137,159
- Dr. Uri GeigerIndependent Director$124,659
- Mr. R. Scott HuennekensIndependent Director
- Ms. Rakhi KumarIndependent Director$137,159
- Mr. Joseph LacobIndependent Director$122,159
- Ms. Renee RyanIndependent Director$134,659
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 55
- Social
- 33
- Governance
- 57
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neuropace Inc has several strengths that contribute to its success in the market. These strengths include:
Weaknesses
- Despite its strengths, Neuropace Inc also has a few weaknesses that it needs to address in order to maintain its competitive position:
Opportunities
- Neuropace Inc can capitalize on several opportunities in the market to further expand its business:
Threats
- Neuropace Inc faces certain threats that could impact its growth and market position negatively:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.